Technical Analysis for SGMO - Sangamo BioSciences, Inc.

Grade Last Price % Change Price Change
grade F 8.46 -2.98% -0.26
SGMO closed down 2.98 percent on Wednesday, February 20, 2019, on 1.16 times normal volume.

Earnings due: Feb 28

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical SGMO trend table...

Date Alert Name Type % Chg
Feb 20 Wide Bands Range Expansion 0.00%
Feb 20 Down 3 Days in a Row Weakness 0.00%
Feb 19 Wide Bands Range Expansion -2.98%
Feb 15 New Downtrend Bearish -3.75%
Feb 15 180 Bearish Setup Bearish Swing Setup -3.75%
Feb 15 Calm After Storm Range Contraction -3.75%
Feb 15 Narrow Range Bar Range Contraction -3.75%
Feb 15 Wide Bands Range Expansion -3.75%
Feb 14 Calm After Storm Range Contraction -6.00%
Feb 14 Narrow Range Bar Range Contraction -6.00%

Older signals for SGMO ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Its ZFPs could be engineered to make ZFP nucleases (ZFNs) proteins, which could be used to modify DNA sequences in various ways; and ZFP transcription factors (ZFP TFs) proteins that could be used to turn genes on or off. The company's principal ZFP therapeutic is SB-728-T, a ZFN-modified autologous T-cell product, which is in Phase II and Phase I/II clinical trials for the treatment of human immunodeficiency virus and acquired immunodeficiency syndrome. It also develops SB-313xTZ that is in Phase I clinical trial for the treatment of glioblastoma. In addition, the company has ZFP therapeutic pre-clinical stage programs for hemophilia A and B, and huntington's disease; and proprietary programs in the areas of hemoglobinopathies and lysosomal storage disorders. Further, it has ZFP therapeutic research stage programs in the areas of other monogenic diseases, including certain immunodeficiency disorders. The company has collaboration, research, and license agreements with Shire AG; Sigma-Aldrich Corporation; Dow AgroSciences LLC; Genentech, Inc.; Open Monoclonal Technology, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. Sangamo Biosciences, Inc. was founded in 1995 and is headquartered in Richmond, California.
Biotechnology Life Sciences Emerging Technologies Molecular Biology Glioblastoma Huntington's Disease Hemoglobinopathies Hemophilia A Hoffmann La Roche Lysosomal Storage Disorders
Is SGMO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 27.5
52 Week Low 6.26
Average Volume 2,145,687
200-Day Moving Average 13.6927
50-Day Moving Average 10.8616
20-Day Moving Average 10.24
10-Day Moving Average 8.909
Average True Range 0.8656
ADX 27.9
+DI 14.2406
-DI 36.6916
Chandelier Exit (Long, 3 ATRs ) 10.1932
Chandelier Exit (Short, 3 ATRs ) 8.8568
Upper Bollinger Band 13.4001
Lower Bollinger Band 7.0799
Percent B (%b) 0.22
BandWidth 61.720703
MACD Line -0.7682
MACD Signal Line -0.5751
MACD Histogram -0.1931
Fundamentals Value
Market Cap 709.55 Million
Num Shares 83.9 Million
EPS -0.81
Price-to-Earnings (P/E) Ratio -10.44
Price-to-Sales 42.92
Price-to-Book 5.17
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.59
Resistance 3 (R3) 9.61 9.27 9.40
Resistance 2 (R2) 9.27 8.98 9.25 9.33
Resistance 1 (R1) 8.86 8.80 8.69 8.84 9.27
Pivot Point 8.52 8.52 8.43 8.50 8.52
Support 1 (S1) 8.11 8.23 7.94 8.09 7.65
Support 2 (S2) 7.77 8.05 7.75 7.59
Support 3 (S3) 7.36 7.77 7.52
Support 4 (S4) 7.34